PermeaDerm® vs. Mepilex-Ag® in Promoting Healing of Partial-thickness Burn Wounds
Launched by THE UNIVERSITY OF TEXAS MEDICAL BRANCH, GALVESTON · Jul 27, 2018
Trial Information
Current as of July 23, 2025
Withdrawn
Keywords
ClinConnect Summary
In this prospective, randomized parallel study, the effectiveness of the wound dressings currently used at our institution for partial-thickness burn wounds will be compared: PermeaDerm®, and silver coated foam dressing Mepilex Ag®.This study is therefore considered a minimal risk study. Procedures related to research apart from randomization to one of the dressings, will include review of medical records, non-invasive wound and scar assessments and additional photographs.
60 patients with partial thickness burns meeting the inclusion criteria of the study will be enrolled to receive eithe...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Superficial partial thickness burn injury due to flame burn, scald injury or contact burn that does not require excision and grafting
- • Total Body Surface Area burned (TBSA) total ≤30 %
- • Admission within 72 hours of burn injury
- • Non-infected wound as diagnosed by the attending physician upon admission
- • Treated as an outpatient or in an observational setting
- Exclusion Criteria:
- • Patient younger than 6 months
- • Causes other than contact burn, flame or scald injuries (i.e., electrical, chemical or frostbite)
- • Admission time greater than 72 hours after the injury
- • Wounds noted to be infected at admission
- • Previous treatment efforts such as previous debridement, silver sulfadiazine ointment or other pseudo eschar-forming topical agents
- • Pregnancy/lactation
About The University Of Texas Medical Branch, Galveston
The University of Texas Medical Branch (UTMB) in Galveston is a leading academic institution dedicated to advancing health through innovative research, education, and clinical care. As a prominent sponsor of clinical trials, UTMB leverages its extensive resources, multidisciplinary expertise, and commitment to excellence to facilitate groundbreaking studies that address critical health challenges. With a focus on translating scientific discoveries into effective therapies, UTMB fosters collaboration among researchers, clinicians, and participants to enhance patient outcomes and contribute to the overall advancement of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Galveston, Texas, United States
Patients applied
Trial Officials
Ludwik K Branski, MD
Principal Investigator
The University of Texas Medical Branch, Galveston
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials